Revenue for the period is projected to reach between US$120 million and US$125 million, marking a significant increase over the US$101 million reported during the same window in 2025. This growth is underpinned by the company's proprietary technology platforms, which have been applied to more than 380 drug discovery programs. Key collaborations with AstraZeneca and Bristol Myers Squibb, alongside the rapid scaling of the Nona Biosciences business unit, have provided a recurring revenue stream that effectively de-risks the company's financial profile.
Harbour BioMed Hits Seventh Consecutive Profitable Half-Year
With an expected profit between US$62 million and US$67 million for the first half of 2026, Harbour BioMed has solidified its transition into a sustained, profitable enterprise. The biopharmaceutical firm attributes this milestone to a robust licensing model and high-value strategic partnerships with global pharmaceutical giants.
Beyond traditional licensing, the company is aggressively integrating artificial intelligence into its R&D workflow. Its Hu-mAtrIx AI platform, launched in late 2025, has already achieved a 78.5% hit rate in antibody generation. By combining these AI capabilities with a clinical pipeline that includes nearly 30 candidates for immunology and oncology, Harbour BioMed is pivoting from a technology adopter to a primary driver of next-generation biologics. The firm continues to advance its lead assets, such as the anti-FcRn antibody batoclimab, which has already completed its full clinical development pathway in China.
Comments (0)
No comments yet. Be the first!